Assuntos
Humanos , Fumar , Tabagismo/etiologia , Nicotiana/química , Brasil , Fumaça , Fumar/epidemiologia , Indústria do TabacoRESUMO
Lung cancer is one of the most commonly occuring malignancies in the world. In ccontrast to other type of cancer, the death rates from lung cancer decrease has been observed in its death rates in the United States and Canada, but not in developing countries, where, in contrast, it continue to rise. These differences among countries are attribued to smoking habits that are decreasing in developed countries, as result of anti-smoking programs launched by goverments to diminish tobacco use and educate the population.Lunf cancer remains a health care problem. Worldwide, only 13-15% of the patients who develop lung cancer survive 5 years. Approximately 75-80of lung carcinomas are non-small cell lung carcinomas (NSCLC), whereas the remaining 20-25% are small cell lung carcinmas (SCLC). The distiction between SCLC and NSCL is a pragmatic clinical classification to standardize management and therapy, since several differences in the treatment strategies exist between NSCL and SCLC. The major distinction between in term of treatment is that far more ofen NSCL is candidate for surgery. In addition, differences also exist in the epidemiology, etiology, pathology, clinical features, stating, prognostic factors and response to chemotherapy. The focus of this thesis is on NSCLC.
Assuntos
Masculino , Feminino , Humanos , Neoplasias PulmonaresRESUMO
Os programas de seguimento pós-tratamento do câncer de mama são heterogêneos, variando entre o centros de tratamento e os profissionais envolvidos. Esses programas têm como denominador comum o gasto de tempo, dinheiro e a falta de uma avaliação criteriosa sobre a sua efetividade. Este artigo de revisão apresenta argumentos para uma mudança na abordagem das pacientes durante o seguimento, enfocando sua efetividade e real impacto na sobrevida